These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12928274)

  • 1. Latanoprost in port wine stain related paediatric glaucoma.
    Ong T; Chia A; Nischal KK
    Br J Ophthalmol; 2003 Sep; 87(9):1091-3. PubMed ID: 12928274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy of latanoprost in primary congenital glaucoma.
    Uva MG; Avitabile T; Reibaldi M; Bucolo C; Drago F; Quaranta L; Lionetti E; Longo A
    Eye (Lond); 2014 Jan; 28(1):53-7. PubMed ID: 24158022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effectiveness of latanoprost for the treatment of pediatric glaucoma].
    Urban B; Bakunowicz-Lazarczyk A; Mrugacz M; Oziebło-Kupczyk M
    Klin Oczna; 2004; 106(1-2 Suppl):243-4. PubMed ID: 15510514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Latanoprost for uncontrolled glaucoma in a compassionate case protocol.
    Patelska B; Greenfield DS; Liebmann JM; Wand M; Kushnick H; Ritch R
    Am J Ophthalmol; 1997 Sep; 124(3):279-86. PubMed ID: 9439353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Five years retrospective study of latanoprost glaucoma treatment].
    Závorková M; Susický P
    Cesk Slov Oftalmol; 2007 Jul; 63(4):292-8. PubMed ID: 17682609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latanoprost : an update of its use in glaucoma and ocular hypertension.
    Perry CM; McGavin JK; Culy CR; Ibbotson T
    Drugs Aging; 2003; 20(8):597-630. PubMed ID: 12795627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Latanoprost in glaucoma associated with Sturge-Weber syndrome: benefits and side-effects.
    Altuna JC; Greenfield DS; Wand M; Liebmann JM; Taglia DP; Kaufman PL; Cioffi GA; Lee DA; Robin AL; Crichton A; Costa VP; Ritch R
    J Glaucoma; 1999 Jun; 8(3):199-203. PubMed ID: 10376261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of latanoprost additive therapy on uncontrolled glaucoma.
    Bayer A; Tas A; Sobaci G; Henderer JD
    Ophthalmologica; 2002; 216(6):443-8. PubMed ID: 12566890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of additive preoperative latanoprost treatment on the outcome of filtration surgery.
    Berthold S; Pfeiffer N
    Graefes Arch Clin Exp Ophthalmol; 2006 Aug; 244(8):1029-34. PubMed ID: 16341541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of latanoprost and timolol in pediatric glaucoma: a phase 3, 12-week, randomized, double-masked multicenter study.
    Maeda-Chubachi T; Chi-Burris K; Simons BD; Freedman SF; Khaw PT; Wirostko B; Yan E;
    Ophthalmology; 2011 Oct; 118(10):2014-21. PubMed ID: 21680022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome.
    Yang CB; Freedman SF; Myers JS; Buckley EG; Herndon LW; Allingham RR
    Am J Ophthalmol; 1998 Oct; 126(4):600-2. PubMed ID: 9780111
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical predictors of latanoprost treatment effect.
    Bayer A; Henderer JD; Kwak T; Myers J; Fontanarosa J; Spaeth GL
    J Glaucoma; 2005 Aug; 14(4):260-3. PubMed ID: 15990603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies.
    Bayer A; Weiler W; Oeverhaus U; Skrotzki FE; Stewart WC;
    J Ocul Pharmacol Ther; 2004 Dec; 20(6):470-8. PubMed ID: 15684807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of age, diagnosis, and history of glaucoma surgery on outcomes in pediatric patients treated with latanoprost.
    Maeda-Chubachi T; Chi-Burris K; Simons B; Brémond-Gignac D; Freedman S; Khaw PT; Wirostko B; Yan E;
    J Glaucoma; 2013; 22(8):614-9. PubMed ID: 23524858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, 36-month, post-marketing efficacy and tolerability study in Sweden and Finland of latanoprost versus non-prostaglandin therapy in patients with glaucoma or ocular hypertension.
    Friström B; Uusitalo H
    Acta Ophthalmol; 2010 Feb; 88(1):37-43. PubMed ID: 19900212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma.
    Ang A; Reddy MA; Shepstone L; Broadway DC
    Br J Ophthalmol; 2004 May; 88(5):630-4. PubMed ID: 15090413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 24-hour efficacy of the bimatoprost-timolol fixed combination versus latanoprost as first choice therapy in subjects with high-pressure exfoliation syndrome and glaucoma.
    Konstas AG; Holló G; Mikropoulos DG; Haidich AB; Dimopoulos AT; Empeslidis T; Teus MA; Ritch R
    Br J Ophthalmol; 2013 Jul; 97(7):857-61. PubMed ID: 23686322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Latanoprost in pediatric glaucoma--pediatric exposure over a decade.
    Black AC; Jones S; Yanovitch TL; Enyedi LB; Stinnett SS; Freedman SF
    J AAPOS; 2009 Dec; 13(6):558-62. PubMed ID: 20006816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glaucoma in children with facial port wine stain.
    Bayoumi NHL; Elsayed EN
    Eur J Ophthalmol; 2020 Jan; 30(1):168-174. PubMed ID: 30563364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.